GENERAL CARDIOLOGY: Pulmonary arterial hypertension: new ideas and perspectives
Open Access
- 1 April 2001
- Vol. 85 (4) , 475-480
- https://doi.org/10.1136/heart.85.4.475
Abstract
Familial PPH has an incidence of at least 6% among all cases of PPH; it is an autosomal dominant disorder with reduced penetrance and genetic anticipation, and has been mapped to a locus designatedPPH1 on chromosome 2q33. The mutations interest the gene BMPR2, encoding a transforming growth factor β (TGF-β) type II receptor (BMPR-II) that is located in the cell membrane.3 TGF-β is representative of a large family of small polypeptides that have many different effects on growth and development. In fact, depending on the cell type, the TGF-β pathway influences many different processes such as growth, mobility, angiogenesis, immunosuppression, and apoptosis. Interestingly, mutations in the BMPR-II gene have also been found in more than 20% of human colorectal cancers. A link between PPH and tumorigenesis has been suspected in the past,4 based on exuberant proliferative vascular changes of pulmonary arteries and on monoclonal endothelial cell proliferation of plexiform lesions.5 BMPR2 germline mutations have been detected in 55% of cases of familial PPH and also in 26% of sporadic cases of PPH, raising the possibility that familial cases are more frequent than expected.6 Until now 46 different mutations of BMPR2 have been identified in PPH patients, and most of them produce a loss of function for the BMPR-II receptor.7 Thus, haploinsufficiency seems to be the molecular mechanism that initiates PPH. On the other hand, the high frequency of “true” sporadic PPH cases and reduced penetrance of familial PPH suggests that additional triggers are required for the development of the disease. Such mechanisms could be a second somatic mutation within an unstable BMPR-II pathway8 or any stimulus able to disrupt pulmonary vascular cell growth control. It is obvious that the identification of the gene responsible for familial PPH and for some cases of sporadic PPH represents a milestone in our understanding of this severe condition, and it will provide new insights into research strategies in pulmonary hypertension.Keywords
This publication has 26 references indexed in Scilit:
- Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary HypertensionCirculation, 2001
- BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary HypertensionAmerican Journal of Human Genetics, 2001
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisitedEuropean Respiratory Journal, 1995
- Do Patients With Primary Pulmonary Hypertension Develop Extensive Central Thrombi?Circulation, 1995
- Pulmonary Vascular Lesions Occurring in Patients With Chronic Major Vessel Thromboembolic Pulmonary HypertensionChest, 1993
- Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease?Annals of Internal Medicine, 1991
- Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)Annals of Internal Medicine, 1990
- Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.Circulation, 1989
- Thromboendarterectomy for Chronic, Major-Vessel Thromboembolic Pulmonary HypertensionAnnals of Internal Medicine, 1987